Evaluating Gardasil HPV Vaccine Humoral and Cellular Immune Responses in People With and Without HIV
NCT06624839
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This is a phase 2, open-label study to assess the immunogenicity of the 9-valent human papillomavirus (HPV) recombinant vaccine (Gardasil9) in people born male with current or past exposure to androgen blockers or estrogen (BM-EABE). Investigators will enroll BM-EABE with HIV and HIV negative controls (BM-EABE or men who have sex with a person with a penis (MSPP)) and administer Gardasil9 at timepoints Day 0, Month 2, and Month 6. The immune response to the vaccine will be analyzed at Month 7 (1 month following the final vaccine dose).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Human Papilloma Virus
- Anal Dysplasia
- HIV
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 to 70 years
- Sex
- Male
- Healthy volunteers
- Accepted
- Sponsor
- University of Maryland, Baltimore
- Last updated on ClinicalTrials.gov
- August 5, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Maryland · 1
- RIIS Clinic at Baltimore Safe Haven · Baltimore, MD
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.